Biodesix (BDSX) Operating Expenses (2019 - 2026)

Biodesix (BDSX) has 8 years of Operating Expenses data on file, last reported at $1.4 million in Q1 2026.

• Quarterly Operating Expenses fell 9.99% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $144.0 million (up 346.66% YoY) and the FY2025 annual result came in at $116.4 million, up 9.97% from the prior year.
• Operating Expenses slipped to $1.4 million in Q1 2026, from $111.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $111.6 million in Q4 2025 to a low of -$60.5 million in Q4 2023.
• A 5-year average of $16.2 million and a median of $21.0 million in 2022 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses tumbled 357.57% — and 2025, when it jumped 1251.68%.
• Tracing BDSX's Operating Expenses over 5 years: stood at $23.5 million in 2022, then plunged by 357.57% to -$60.5 million in 2023, then soared by 144.74% to $27.1 million in 2024, then soared by 312.22% to $111.6 million in 2025, then sank by 98.74% to $1.4 million in 2026.
• The last three Operating Expenses figures came in at $1.4 million (Q1 2026), $111.6 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.